Glenmark Pharmaceuticals receives ANDA approval for Frovatriptan Succinate Tablets

14 Mar 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg, the therapeutic equivalent to the reference listed drug product, Frova Tablets, 2.5 mg, of Endo Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending January 2016, the Frova Market achieved annual sales of approximately $87.8 million.

Glenmark’s current portfolio consists of 108 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

2010.50 -25.40 (-1.25%)
01-Jan-2026 14:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1718.85
Dr. Reddys Lab 1250.85
Cipla 1499.55
Zydus Lifesciences 912.30
Lupin 2099.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×